(CercleFinance.com) – Intrasense reported Thursday evening a turnover down 12.8% for the year 2023, penalized by the situation in China.
The medical imaging software designer says it generated annual sales of 3.3 million euros last year, compared to 3.8 million euros in 2022, a figure deemed ‘very disappointing’ by analysts at InvestSecurities.
In the second half alone, activity fell by more than 40% following the freezing of calls for tenders on the Chinese market, a direct consequence of the implementation of anti-corruption measures by Beijing.
‘This campaign (…) has considerably reduced the activity of all manufacturers in the health sector in this area, negatively impacting the company’s commercial dynamics in China,’ explains Intrasense in a press release.
The group also believes that the war in Ukraine keeps the European region in a climate of instability, disrupting the predictability of commercial operations.
The continued uncertainty has led to a postponement of certain calls for tenders expected at the end of 2023, affecting the group’s growth.
If the difficulties in China seem to gradually ease at the beginning of 2024, Intrasense emphasizes that the year 2024 represents a crucial stage with the obtaining of regulatory marking for Myrian expected at the start of the second quarter.
This qualification should allow the group to market an AI-powered solution with high added value in growing markets.
The company also says it is preparing the launch of its new software solution dedicated to oncology for mid-2024, which should again constitute a factor in accelerating growth.
Despite all these announcements, the stock fell by more than 7% on Friday on the Paris Stock Exchange.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on INTRASENSE in real time: